Author

Montserrat Rivero

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

Montserrat Rivero  et al.

THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU
THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU

Montserrat Rivero  et al.

MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
MICROBIOME CHARACTERIZATION IN STOOL FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Montserrat Rivero  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

Montserrat Rivero  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Montserrat Rivero  et al.

CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF MALIGNANT SMALL BOWEL NEOPLASIAS: PROGNOSIS OF A SILENT ENTITY
CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF MALIGNANT SMALL BOWEL NEOPLASIAS: PROGNOSIS OF A SILENT ENTITY

Montserrat Rivero  et al.

LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU

Montserrat Rivero  et al.

IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)
IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT)

Montserrat Rivero  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

Montserrat Rivero  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

Montserrat Rivero  et al.

HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Montserrat Rivero  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Montserrat Rivero  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Montserrat Rivero  et al.

PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE
PROTEOMIC CHARACTERIZATION OF SERUM EXTRACELLULAR VESICLES FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Montserrat Rivero  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Montserrat Rivero  et al.

INCREASED RISK OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ADVANCED FIBROSIS IN INFLAMMATORY BOWEL DISEASE INDEPENDENT OF CLASSIC METABOLIC RISK FACTORS
INCREASED RISK OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ADVANCED FIBROSIS IN INFLAMMATORY BOWEL DISEASE INDEPENDENT OF CLASSIC METABOLIC RISK FACTORS

Montserrat Rivero  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Montserrat Rivero  et al.

CHARACTERISTICS AND MANAGEMENT OF PYODERMA GANGRENOSUM AND ERYTHEMA NODOSUM IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PIONOSO MULTICENTER STUDY
CHARACTERISTICS AND MANAGEMENT OF PYODERMA GANGRENOSUM AND ERYTHEMA NODOSUM IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PIONOSO MULTICENTER STUDY

Montserrat Rivero  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

Montserrat Rivero  et al.

MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU
MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU

Montserrat Rivero  et al.

Item 1 - 20 / 31
1
2